Stockreport

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc.  (LCTX) 
PDF Positive RG6501 (OpRegen® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025Achieved First Milestone Under Worldwide [Read more]